181 related articles for article (PubMed ID: 29169525)
21. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract][Full Text] [Related]
22. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.
Takegawa N; Hayashi H; Iizuka N; Takahama T; Ueda H; Tanaka K; Takeda M; Nakagawa K
Ann Oncol; 2016 May; 27(5):953-5. PubMed ID: 26811347
[No Abstract] [Full Text] [Related]
23. Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against
Fujimura T; Furugaki K; Harada N; Yoshimura Y
Cancer Biol Ther; 2020 Sep; 21(9):863-870. PubMed ID: 32835580
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
[TBL] [Abstract][Full Text] [Related]
25. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
26. Alectinib.
Herden M; Waller CF
Recent Results Cancer Res; 2018; 211():247-256. PubMed ID: 30069772
[TBL] [Abstract][Full Text] [Related]
27. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
28. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
Gilbert JA
Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
[No Abstract] [Full Text] [Related]
29. Clinical Efficacy of Alectinib in Patients with
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
[TBL] [Abstract][Full Text] [Related]
31. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
Yang JC; Ou SI; De Petris L; Gadgeel S; Gandhi L; Kim DW; Barlesi F; Govindan R; Dingemans AC; Crino L; Lena H; Popat S; Ahn JS; Dansin E; Golding S; Bordogna W; Balas B; Morcos PN; Zeaiter A; Shaw AT
J Thorac Oncol; 2017 Oct; 12(10):1552-1560. PubMed ID: 28689043
[TBL] [Abstract][Full Text] [Related]
32. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
33. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
[TBL] [Abstract][Full Text] [Related]
34. Targeted Therapy for Mutation-Driven Metastatic Non-Small-Cell Lung Cancer: Considerations for ALK-Rearranged Tumors.
Mileham KF; Ahmad MN; Kim ES
Oncology (Williston Park); 2019 Apr; 33(4):152-5. PubMed ID: 30990569
[No Abstract] [Full Text] [Related]
35. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.
Toyokawa G; Hirai F; Inamasu E; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y
J Thorac Oncol; 2014 Dec; 9(12):e86-7. PubMed ID: 25393798
[No Abstract] [Full Text] [Related]
36. A selective ALK inhibitor in ALK-rearranged patients.
Yang JC
Lancet Oncol; 2013 Jun; 14(7):564-5. PubMed ID: 23639469
[No Abstract] [Full Text] [Related]
37. Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer.
Hwang A; Iskandar A; Dasanu CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1531-1533. PubMed ID: 30572795
[TBL] [Abstract][Full Text] [Related]
38. Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
Tsuji T; Ozasa H; Aoki W; Aburaya S; Funazo T; Furugaki K; Yoshimura Y; Ajimizu H; Okutani R; Yasuda Y; Nomizo T; Uemasu K; Hasegawa K; Yoshida H; Yagi Y; Nagai H; Sakamori Y; Ueda M; Hirai T; Kim YH
Mol Cancer Res; 2019 Jan; 17(1):212-224. PubMed ID: 30171175
[TBL] [Abstract][Full Text] [Related]
39. Model-Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First-Line Anaplastic Lymphoma Kinase + Non-Small Cell Lung Cancer.
Morcos PN; Liu J; Blumenthal GM; Zhao H
Clin Pharmacol Ther; 2019 Apr; 105(4):826-828. PubMed ID: 30723888
[No Abstract] [Full Text] [Related]
40. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA
J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
